These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 38402609)
1. Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer. Tong X; Patel AS; Kim E; Li H; Chen Y; Li S; Liu S; Dilly J; Kapner KS; Zhang N; Xue Y; Hover L; Mukhopadhyay S; Sherman F; Myndzar K; Sahu P; Gao Y; Li F; Li F; Fang Z; Jin Y; Gao J; Shi M; Sinha S; Chen L; Chen Y; Kheoh T; Yang W; Yanai I; Moreira AL; Velcheti V; Neel BG; Hu L; Christensen JG; Olson P; Gao D; Zhang MQ; Aguirre AJ; Wong KK; Ji H Cancer Cell; 2024 Mar; 42(3):413-428.e7. PubMed ID: 38402609 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study. Zhou Q; Meng X; Sun L; Huang D; Yang N; Yu Y; Zhao M; Zhuang W; Guo R; Hu Y; Pan Y; Shan J; Sun M; Yuan Y; Fan Y; Huang J; Liu L; Chu Q; Wang X; Xu C; Lin J; Huang J; Huang M; Sun J; Zhang S; Zhou H; Wu YL J Thorac Oncol; 2024 Dec; 19(12):1630-1639. PubMed ID: 39127176 [TBL] [Abstract][Full Text] [Related]
3. Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in Ghosh S; Fan F; Powell R; Park YS; Stephan C; Kopetz ES; Ellis LM; Bhattacharya R Ther Adv Med Oncol; 2024; 16():17588359241303302. PubMed ID: 39664300 [TBL] [Abstract][Full Text] [Related]
4. KRAS-G12 inhibitors in lung cancer therapy: unveiling the toxicity profile through a pharmacovigilance study. Li W; Wang W Support Care Cancer; 2024 Nov; 32(12):812. PubMed ID: 39570438 [TBL] [Abstract][Full Text] [Related]
5. Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers. Xiao F; Wang K; Wang X; Li H; Hu Z; Ren X; Huang W; Feng T; Yao L; Lin J; Li C; Zhang Z; Mei L; Zhu X; Zhong W; Xie Z Mol Cancer Ther; 2024 Dec; 23(12):1703-1716. PubMed ID: 39087485 [TBL] [Abstract][Full Text] [Related]
6. Targeting KRAS in pancreatic cancer. Stickler S; Rath B; Hamilton G Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056 [TBL] [Abstract][Full Text] [Related]
7. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling. Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689 [TBL] [Abstract][Full Text] [Related]
8. Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy. Warnecke B; Nagasaka M Drug Des Devel Ther; 2024; 18():5673-5683. PubMed ID: 39654605 [TBL] [Abstract][Full Text] [Related]
9. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone. Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924 [TBL] [Abstract][Full Text] [Related]
10. Quantitative MRI Measurements Capture Pancreatic Cancer and Stroma Reactions to New KRAS Inhibitor. Gupta M; Choi H; Kemp SB; Furth EE; Pickup S; Clendenin C; Orlen M; Rosen M; Liu F; Cao Q; Stanger BZ; Zhou R bioRxiv; 2024 Nov; ():. PubMed ID: 39651222 [TBL] [Abstract][Full Text] [Related]
11. Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer. Higgins JP; Carlisle JW; Moniri NH; Gupta S; Oduah EI; Leal T Future Oncol; 2024 Nov; ():1-9. PubMed ID: 39601038 [TBL] [Abstract][Full Text] [Related]
12. FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer. Kazi A; Kantilal Vasiyani HK; Ghosh D; Bandyopadhyay D; Shah RD; Vudatha V; Trevino J; Sebti SM J Thorac Oncol; 2024 Nov; ():. PubMed ID: 39603412 [TBL] [Abstract][Full Text] [Related]
13. Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment. Wang K; Xu M; Wang Y; Xu C; Hao Y; Song Z Clin Transl Oncol; 2024 Oct; 26(10):2479-2487. PubMed ID: 38625494 [TBL] [Abstract][Full Text] [Related]
14. Dynamic Field Theory of Executive Function: Identifying Early Neurocognitive Markers. McCraw A; Sullivan J; Lowery K; Eddings R; Heim HR; Buss AT Monogr Soc Res Child Dev; 2024 Dec; 89(3):7-109. PubMed ID: 39628288 [TBL] [Abstract][Full Text] [Related]
15. Trends in Surgical and Nonsurgical Aesthetic Procedures: A 14-Year Analysis of the International Society of Aesthetic Plastic Surgery-ISAPS. Triana L; Palacios Huatuco RM; Campilgio G; Liscano E Aesthetic Plast Surg; 2024 Oct; 48(20):4217-4227. PubMed ID: 39103642 [TBL] [Abstract][Full Text] [Related]
16. A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer. Singhal A; Styers HC; Rub J; Li Z; Torborg SR; Kim JY; Grbovic-Huezo O; Feng H; Tarcan ZC; Sahin Ozkan H; Hallin J; Basturk O; Yaeger R; Christensen JG; Betel D; Yan Y; Chio IIC; de Stanchina E; Tammela T Cancer Discov; 2024 Nov; 14(11):2122-2134. PubMed ID: 38975873 [TBL] [Abstract][Full Text] [Related]
17. The effectiveness of abstinence-based and harm reduction-based interventions in reducing problematic substance use in adults who are experiencing homelessness in high income countries: A systematic review and meta-analysis: A systematic review. O'Leary C; Ralphs R; Stevenson J; Smith A; Harrison J; Kiss Z; Armitage H Campbell Syst Rev; 2024 Jun; 20(2):e1396. PubMed ID: 38645303 [TBL] [Abstract][Full Text] [Related]